Valuation dashboard for Oragenics, Inc. (OGEN) with P/E N/A, P/B 0.61, EV/EBITDA 0.22 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.50, OGEN has negative trailing earnings (P/E not meaningful) and an ROE of -144.23%. Market capitalisation stands at $2M.
Balance sheet quality for OGEN: current ratio of 5.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.61 |
| EV / EBITDA | 0.22 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.52 |
| vs Current Price | +204.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OGEN | Oragenics, Inc. | $2M | 0.61 | -144.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.50 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | -144.23% |
| Return on Invested Capital | -279.54% |
| Return on Assets | -183.59% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks